The AP-1/NF-κB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia

RODRIGO MOORE-CARRASCO², SÍLVIA BUSQUETS¹, VANESSA ALMENDRO¹, MOORTHY PALANKI¹, FRANCISCO J. LÓPEZ-SORIANO¹ and JOSEP M. ARGILÉS¹

¹Departament de Bioquímica i Biologia Molecular, Universitat de Barcelona, Barcelona, Spain; ²Departamento de Bioquímica Clínica e Immunohematologia, Universidad de Talca, Talca, Chile; ³Celgene, 4550 Towne Centre Court, San Diego, CA 92121, USA

Received November 23, 2006; Accepted January 22, 2007

Abstract. Daily treatment of rats bearing the cachectic Yoshida AH-130 ascites hepatoma with the double inhibitor of NF-κB and AP-1 SP100030 at a dose of 1 mg/kg of body weight resulted in a clear amelioration of the cachectic effect, especially at the level of skeletal muscle. Thus, tumour-bearing rats treated with SP100030 showed a significant recovery in the weights of gastrocnemius, EDL, tibialis and cardiac muscles. In addition, treatment with the inhibitor affected both liver and kidney weights. The amelioration in muscle weight was accompanied by an increase in MyoD gene expression, the main transcription factor of muscle tissue involved in muscle differentiation, in gastrocnemius muscle. At the dose used in this study, SP100030 was an effective inhibitor of AP-1; however, the NF-κB transcription factor was not affected. The effects of the inhibitor seem to be at the level of proteolysis since lower total proteolytic rates were found when incubating isolated rat muscles in the presence of SP100030. The inhibitor influenced the gene expression of the ubiquitin-conjugating enzyme E2, in skeletal muscle of tumour-bearing rats; this enzyme seems to be the main regulator of the activity of the main proteolytic system involved during cancer cachexia, the ubiquitin-proteasome system. In conclusion, treatment of cachectic tumour-bearing rats with SP100030 results in an amelioration of the muscle wasting effect, suggesting that the AP-1 signaling cascade plays an important role in the signaling of muscle wasting associated with disease.

Introduction

Malignant neoplasms frequently induce a progressive loss of lean body mass in the host, associated with marked alterations in endocrine and metabolic homeostasis. Skeletal muscle tissue, which accounts for almost half of the whole body protein mass, is severely affected in cancer cachexia (1-3). Muscle wasting in cachexia is associated with enhanced protein turnover rates (4,5). In addition, cachexia tends to develop at rather late stages of neoplastic disease. Thus, preventing muscle wasting in cancer patients is of great potential clinical interest.

The Yoshida AH-130 rat ascites hepatoma is a suitable model system for studying the mechanisms involved in the establishment of cachexia. Its growth in the host causes rapid and progressive loss of body weight and tissue wasting, particularly in skeletal muscle. Acceleration of tissue protein breakdown accounts for most of the wasting in AH-130 bearers. In particular, skeletal muscle hypercatabolism involves hyperactivation of the ATP-ubiquitin-dependent proteolytic system (6,7). Detectable plasma levels of tumour necrosis factor-α (TNF) and perturbations in hormonal homeostasis (4,8) may play an important role in forcing metabolic balance towards the catabolic side.

Several cytokines have been shown to mimic many of the metabolic abnormalities found in the cancer patient during cachexia. Administration of TNF to rats results in an increased skeletal muscle proteolysis associated with an increase in both gene expression and higher levels of free and conjugated ubiquitin (4,9,10). Other cytokines such as IL-1 or IFN-γ are also able to activate ubiquitin gene expression (11-15). Therefore, TNF [alone or in combination with other cytokines (16-20)] seems to mediate most of the changes concerning nitrogen metabolism associated with cachectic states. In addition to the massive muscle protein loss, during cancer cachexia, similarly to what is observed in skeletal muscle of chronic heart failure patients suffering from cardiac cachexia (21), muscle DNA fragmentation is increased and, thus, apoptosis (22). TNF can mimic the apoptotic response in muscle of healthy animals (23).

In order to define successful approximations for the pharmacological treatment of cachexia, a good knowledge
of the different intracellular signaling pathways linked to the muscle wasting process is essential. This is especially important since a plethora of mediators, both humoral and tumoural, that have been proposed as being responsible for the muscle protein abnormalities found in cachexia. From this point of view it is interesting to note that previous studies have shown an involvement of both NF-κB and AP-1 signaling cascades during sepsis (24). In COPD patients, with evident muscle wasting, NF-κB has also been proposed as being involved in skeletal muscle (25). In an interesting investigation, Cai et al concluded, using an IκB kinase beta transgenic model, that NF-κB has a marked role in muscle wasting (26). The SP100030 compound has previously been used in pre-clinical studies involving arthritis (27), and host-versus-graft disease (28).

Bearing all this in mind, the main objective of the present study was to test if blockade of the two transcription factors, NF-κB and AP-1, was able to interfere with muscle wasting in cachectic tumour-bearing rats. Therefore, we used a double NF-κB and AP-1 inhibitor, SP100030, and examined the effects on the tumour growth and cachexia generated by the rat Yoshida AH-130 ascites hepatoma.

Materials and methods

Animals. Male Wistar rats (Interfauna, Barcelona, Spain), of 5 weeks of age, were used in the experiment. The animals were maintained at 22±2°C with a regular light-dark cycle (light on from 08:00 a.m. to 08:00 p.m.) and had free access to food and water. The food intake was measured daily. All animal manipulations were made in accordance with the European Community guidelines for the use of laboratory animals.

Tumour inoculation and treatment. Rats were divided into two groups, controls and tumour hosts. The latter received an intraperitoneal inoculum of 10^6 AH-130 Yoshida ascites hepatoma cells obtained from exponential tumours (29). Both tumour and non-tumour bearing animals were subdivided into two groups according to treatment. The treated groups were injected subcutaneously with a daily dose of SP100030 (1 mg/kg body weight) dissolved in 1% carboxymethyl cellulose (carrier). The non-treated groups received an equivalent (1 mg/kg body weight) dissolved in 1% carboxymethyl cellulose. The animals were weighed and anesthetized with an i.p. injection of ketamine/xylazine mixture (3:1) (Imalgene® and Rompun®, respectively). The tumour was harvested from the peritoneal cavity and its volume and cellularity evaluated. The animals were sacrificed 7 days after tumour transplantation, and the muscles were removed and weighed. The non-treated groups received an equivalent (1 mg/kg body weight) dissolved in 1% carboxymethyl cellulose.

Bearing all this in mind, the main objective of the present study was to test if blockade of the two transcription factors, NF-κB and AP-1, was able to interfere with muscle wasting in cachectic tumour-bearing rats. Therefore, we used a double NF-κB and AP-1 inhibitor, SP100030, and examined the effects on the tumour growth and cachexia generated by the rat Yoshida AH-130 ascites hepatoma.

Materials and methods

Animals. Male Wistar rats (Interfauna, Barcelona, Spain), of 5 weeks of age, were used in the experiment. The animals were maintained at 22±2°C with a regular light-dark cycle (light on from 08:00 a.m. to 08:00 p.m.) and had free access to food and water. The food intake was measured daily. All animal manipulations were made in accordance with the European Community guidelines for the use of laboratory animals.

Tumour inoculation and treatment. Rats were divided into two groups, controls and tumour hosts. The latter received an intraperitoneal inoculum of 10^6 AH-130 Yoshida ascites hepatoma cells obtained from exponential tumours (29). Both tumour and non-tumour bearing animals were subdivided into two groups according to treatment. The treated groups were injected subcutaneously with a daily dose of SP100030 (1 mg/kg body weight) dissolved in 1% carboxymethyl cellulose (carrier). The non-treated groups received an equivalent (1 mg/kg body weight) dissolved in 1% carboxymethyl cellulose.

Bearing all this in mind, the main objective of the present study was to test if blockade of the two transcription factors, NF-κB and AP-1, was able to interfere with muscle wasting in cachectic tumour-bearing rats. Therefore, we used a double NF-κB and AP-1 inhibitor, SP100030, and examined the effects on the tumour growth and cachexia generated by the rat Yoshida AH-130 ascites hepatoma.

Materials and methods

Animals. Male Wistar rats (Interfauna, Barcelona, Spain), of 5 weeks of age, were used in the experiment. The animals were maintained at 22±2°C with a regular light-dark cycle (light on from 08:00 a.m. to 08:00 p.m.) and had free access to food and water. The food intake was measured daily. All animal manipulations were made in accordance with the European Community guidelines for the use of laboratory animals.

Tumour inoculation and treatment. Rats were divided into two groups, controls and tumour hosts. The latter received an intraperitoneal inoculum of 10^6 AH-130 Yoshida ascites hepatoma cells obtained from exponential tumours (29). Both tumour and non-tumour bearing animals were subdivided into two groups according to treatment. The treated groups were injected subcutaneously with a daily dose of SP100030 (1 mg/kg body weight) dissolved in 1% carboxymethyl cellulose (carrier). The non-treated groups received an equivalent (1 mg/kg body weight) dissolved in 1% carboxymethyl cellulose.

Bearing all this in mind, the main objective of the present study was to test if blockade of the two transcription factors, NF-κB and AP-1, was able to interfere with muscle wasting in cachectic tumour-bearing rats. Therefore, we used a double NF-κB and AP-1 inhibitor, SP100030, and examined the effects on the tumour growth and cachexia generated by the rat Yoshida AH-130 ascites hepatoma.

Materials and methods

Animals. Male Wistar rats (Interfauna, Barcelona, Spain), of 5 weeks of age, were used in the experiment. The animals were maintained at 22±2°C with a regular light-dark cycle (light on from 08:00 a.m. to 08:00 p.m.) and had free access to food and water. The food intake was measured daily. All animal manipulations were made in accordance with the European Community guidelines for the use of laboratory animals.

Tumour inoculation and treatment. Rats were divided into two groups, controls and tumour hosts. The latter received an intraperitoneal inoculum of 10^6 AH-130 Yoshida ascites hepatoma cells obtained from exponential tumours (29). Both tumour and non-tumour bearing animals were subdivided into two groups according to treatment. The treated groups were injected subcutaneously with a daily dose of SP100030 (1 mg/kg body weight) dissolved in 1% carboxymethyl cellulose (carrier). The non-treated groups received an equivalent (1 mg/kg body weight) dissolved in 1% carboxymethyl cellulose.

Bearing all this in mind, the main objective of the present study was to test if blockade of the two transcription factors, NF-κB and AP-1, was able to interfere with muscle wasting in cachectic tumour-bearing rats. Therefore, we used a double NF-κB and AP-1 inhibitor, SP100030, and examined the effects on the tumour growth and cachexia generated by the rat Yoshida AH-130 ascites hepatoma.

Materials and methods

Animals. Male Wistar rats (Interfauna, Barcelona, Spain), of 5 weeks of age, were used in the experiment. The animals were maintained at 22±2°C with a regular light-dark cycle (light on from 08:00 a.m. to 08:00 p.m.) and had free access to food and water. The food intake was measured daily. All animal manipulations were made in accordance with the European Community guidelines for the use of laboratory animals.

Tumour inoculation and treatment. Rats were divided into two groups, controls and tumour hosts. The latter received an intraperitoneal inoculum of 10^6 AH-130 Yoshida ascites hepatoma cells obtained from exponential tumours (29). Both tumour and non-tumour bearing animals were subdivided into two groups according to treatment. The treated groups were injected subcutaneously with a daily dose of SP100030 (1 mg/kg body weight) dissolved in 1% carboxymethyl cellulose (carrier). The non-treated groups received an equivalent (1 mg/kg body weight) dissolved in 1% carboxymethyl cellulose.

Bearing all this in mind, the main objective of the present study was to test if blockade of the two transcription factors, NF-κB and AP-1, was able to interfere with muscle wasting in cachectic tumour-bearing rats. Therefore, we used a double NF-κB and AP-1 inhibitor, SP100030, and examined the effects on the tumour growth and cachexia generated by the rat Yoshida AH-130 ascites hepatoma.

Materials and methods

Animals. Male Wistar rats (Interfauna, Barcelona, Spain), of 5 weeks of age, were used in the experiment. The animals were maintained at 22±2°C with a regular light-dark cycle (light on from 08:00 a.m. to 08:00 p.m.) and had free access to food and water. The food intake was measured daily. All animal manipulations were made in accordance with the European Community guidelines for the use of laboratory animals.

Tumour inoculation and treatment. Rats were divided into two groups, controls and tumour hosts. The latter received an intraperitoneal inoculum of 10^6 AH-130 Yoshida ascites hepatoma cells obtained from exponential tumours (29). Both tumour and non-tumour bearing animals were subdivided into two groups according to treatment. The treated groups were injected subcutaneously with a daily dose of SP100030 (1 mg/kg body weight) dissolved in 1% carboxymethyl cellulose (carrier). The non-treated groups received an equivalent (1 mg/kg body weight) dissolved in 1% carboxymethyl cellulose.
Statistical analysis. Statistical analysis of the data was performed by means of the Student's t-test.

Results and Discussion

Epidemiological data indicate that cachexia affects at least 30% of the patients who died of advanced cancer and that it is responsible for the death of at least 22% of cancer patients (37,38). It is a complex syndrome characterized by weight loss, anorexia and profound disturbances in metabolism which inflict serious muscle wasting. Several experimental models have been used to study muscle wasting during cancer. The rat Yoshida AH-130 ascites hepatoma is a suitable model system to study the mechanisms involved in the establishment of cachexia. The growth causes in the host a rapid and progressive loss of body weight and tissue waste, particularly in skeletal muscle (29). Unfortunately, there seems to be a plethora of mediators involved in the activation of muscle protein degradation during cancer cachexia. Thus, several tumour compounds have been proposed as activators of protein breakdown. Proteolysis-inducing Factor (PIF) was reported involved in the activation of muscle wasting in an experimental mouse model of cancer cachexia (39). Additionally, cytokines, TNF and IL-6 in particular, have been reported to have a role in wasting in skeletal muscle during cancer (4,16,17,31,40-44). Changes in hormone concentrations and/or sensitivity (insulin-glucocorticoids) may also be involved in wasting (45). Therefore, the design of an effective therapeutic strategy is rather complicated due to the number of different mediators.

Considering the above, it could be more effective to see if therapeutic strategies may be directed to an intracellular common target, since some of the compounds mentioned seem to share similar intracellular signaling pathways. However, few studies have considered the intracellular signaling pathways associated with muscle wasting. Penner et al reported that during experimentally-induced sepsis there was an activation of both NF-κB and AP-1 signaling pathways (24).

In humans, muscle wasting associated with the chronic obstructive pulmonary syndrome (COPD) seems to be associated with activation of NF-κB associated with degradation of IκBα (25).

Previous results indicate that NF-κB is involved in the intracellular actions of PIF, one of the main tumoural compounds involved in cancer cachexia (46). In addition, results from our laboratory indicate that in experimental cancer cachexia there is an activation of AP-1 associated with the process of muscle wasting (47). Therefore, we decided to provide a table summarizing the effects of SP100030 on food intake, body and tissue weight in rats bearing the Yoshida AH-130 ascites hepatoma.

### Table I. Effects of SP100030 on food intake, body and tissue weight in rats bearing the Yoshida AH-130 ascites hepatoma.

<table>
<thead>
<tr>
<th></th>
<th>C (11)</th>
<th>CT (12)</th>
<th>T (10)</th>
<th>TT (12)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Body weight and food intake</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial body weight (g)</td>
<td>134±3</td>
<td>134±2</td>
<td>138±3</td>
<td>135±2</td>
</tr>
<tr>
<td>Final body weight (g)</td>
<td>175±5</td>
<td>172±3</td>
<td>128±4</td>
<td>129±4</td>
</tr>
<tr>
<td>Body weight increase (g)</td>
<td>30±2</td>
<td>29±2</td>
<td>-6±2</td>
<td>-5±1</td>
</tr>
<tr>
<td>Carcass (g)</td>
<td>97±2</td>
<td>94±1</td>
<td>70±2</td>
<td>77±3</td>
</tr>
<tr>
<td>Total food intake (g)</td>
<td>120±2</td>
<td>125±1</td>
<td>95±1</td>
<td>109±5</td>
</tr>
<tr>
<td><strong>Muscle weights</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tibialis (mg)</td>
<td>212±4</td>
<td>201±4</td>
<td>152±5</td>
<td>175±10</td>
</tr>
<tr>
<td>EDL (mg)</td>
<td>49±1</td>
<td>47±1</td>
<td>34±2</td>
<td>43±3</td>
</tr>
<tr>
<td>Gastrocnemius (mg)</td>
<td>685±18</td>
<td>661±17</td>
<td>500±23</td>
<td>586±31</td>
</tr>
<tr>
<td>Soleus (mg)</td>
<td>40±2</td>
<td>42±2</td>
<td>32±2</td>
<td>34±1</td>
</tr>
<tr>
<td><strong>Adipose tissue weights</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WAT (mg)</td>
<td>821±56</td>
<td>960±85</td>
<td>408±61</td>
<td>513±70</td>
</tr>
<tr>
<td>BAT (mg)</td>
<td>224±27</td>
<td>240±23</td>
<td>113±13</td>
<td>166±25</td>
</tr>
<tr>
<td><strong>Organ weights</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver (mg)</td>
<td>5435±146</td>
<td>5413±129</td>
<td>4680±218</td>
<td>5044±162</td>
</tr>
<tr>
<td>Heart (mg)</td>
<td>416±12</td>
<td>422±11</td>
<td>315±7</td>
<td>362±10</td>
</tr>
<tr>
<td>Kidneys (mg)</td>
<td>523±13</td>
<td>509±14</td>
<td>353±14</td>
<td>427±18</td>
</tr>
<tr>
<td>Spleen (mg)</td>
<td>379±15</td>
<td>395±22</td>
<td>317±30</td>
<td>320±32</td>
</tr>
<tr>
<td><strong>Tumour cell content</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data are means ± SEM with the number of animals indicated in parentheses. Tissue and organ weights are expressed as mg per 100 g initial body weight (BW). Bilateral tissues are the average of the two. Carcass basically represents muscle, skin and bone. In tumour-bearers, body weight represents total body weight minus tumour mass. Tumour cell content is expressed in millions of cells. Statistical significance of the results (Student's t-test): Control vs. tumour: *p≤0.05; †p≤0.01; ‡p≤0.001 and treatment vs. none: *p≤0.05; †p≤0.01; ‡p≤0.001. Experimental groups: C, control non-treated; CT, control treated; T, tumour-bearing non-treated; TT, tumour-bearing treated. WAT, white adipose tissue; BAT, brown adipose tissue; EDL, extensor digitorum longus.
investigate if blockage of both NF-κB and AP-1 signaling cascades could be an effective therapeutic approach for the treatment of cancer cachexia.

The results presented in Table I show the adequacy of the Yoshida AH-130 ascites hepatoma for studies concerning experimental cancer cachexia. The implantation of the tumour results in considerable body weight loss (27%) which is accompanied by a marked decrease in food intake (21%). As can be seen in Table I, muscle weights are particularly affected by tumour burden with significant decreases: gastrocnemius (27%), soleus (20%), EDL (31%) and tibialis (28%). In addition, there is a significant decrease in heart (24%), kidneys (33%) and liver (14%) weights. At the level of adipose tissue, the presence of the tumour also results in a considerable decrease in both white (50%) and brown (50%) fat depots. Of note, treatment with the SP100030 inhibitor resulted in amelioration of the weight loss for most of the muscles studied (gastrocnemius, tibialis and EDL). In addition, the heart weight was affected by the treatment, since there was a significant increase in the weight of this organ in relation with the tumour-bearing non-treated group (Table I). Weight loss amelioration was also observed in the kidneys.
All of these changes inflicted by the inhibitor treatment were not reflected in total animal weight; however, a tendency for carcass (basically bone and muscle) to increase was observed, although statistical significance was not reached (Table I). The inhibitor treatment resulted in an increase in food intake (5 and 15% for control treated and tumour treated, respectively), this factor possibly contributing to the observed effects of the treatment upon amelioration of muscle weight loss. It should be noted that the inhibitor treatment did not inflict any changes in tumour growth, as presented in Table I.

Previous studies have shown that SP100030 behaves as an effective double inhibitor of both NF-κB and AP-1 (48). We decided to test whether this was the case in our experimental set-up and, therefore, we performed an electrophoretic mobility shift assay (EMSA) of the muscle samples and found that, while an effective inhibition of AP-1 (30 and 29% for control and tumour-bearing, respectively) was present, NF-κB did not seem to be altered (Fig. 1). Different in vivo studies have shown the efficacy of the inhibitor for both transcription factors but using much higher doses (10-20 mg/kg bw) (27,28,48,49) than the one we used (1 mg/kg bw). We decided to use this dose to minimize the toxic effects of the inhibitor.

The treatment with the inhibitor also resulted in changes in MyoD transcription factor in gastrocnemius muscles of tumour-bearing rats, as shown in Fig. 2. In the tumour-bearing rats, SP100030 treatment resulted in amelioration of the effect of tumour burden on muscle MyoD gene expression (Fig. 2). These results are in agreement with the recovery in muscle weights inflicted by the inhibitor treatment during tumour burden (Table I). Treatment with the inhibitor did not affect the control, non-tumour bearing animals.

Taking into consideration the fact that, as we have previously reported during experimental cancer cachexia, muscle proteolysis is the main mechanism that is activated and related with wasting (6,7,50), we decided to investigate if the proteolytic rate was affected or not in the tumour bearing rats. We incubated isolated skeletal muscles in an ex vivo set up, as previously described (30-32), and examined the proteolytic rates in the presence or absence of the inhibitor. The results presented in Fig. 3 show that the SP100030 inhibitor significantly reduces the proteolytic rate in incubated muscles (16%). These results seem to indicate that at least the AP-1 signaling cascade is involved in the proteolytic events that take place in skeletal muscle during cancer cachexia. Our group has described that the main proteolytic mechanism involved in the increased proteolytic rate found associated with tumour burden was that of the ubiquitin-proteasome system (6,7,50). Bearing this in mind, we investigated if treatment with the inhibitor affected the ubiquitin system by examining the expression of some components of the ubiquitin system. The results presented in Fig. 4 show that, in spite of the fact that the ubiquitin gene expression does not seem to be affected by the treatment, a lack of activation is observed in the ubiquitin-conjugating enzyme E214K in the treated animals. It has to be pointed out here that this enzyme is considered one of the key regulatory proteins that control the activity of the ubiquitin-proteasome system (51-55).

The results presented herein support our previous studies where we have emphasised the important of the AP-1 signaling cascade, as opposed to the NF-xB one in muscle wasting associated with cancer cachexia. A lack of NF-xB activation was observed in the same experimental model used here (47) and infection of cachectic tumour-bearing animals.
with TAM-67 carrying viruses, a negative dominant of c-jun/ AP-1, results in amelioration of muscle wasting (56). Collectively, the importance of the AP-1 signaling cascade in muscle wasting, at least in experimental cancer cachexia, seems to be very clear. This is important from a therapeutic point of view since this transcription factor seems to be involved in the signaling cascade associated with several cytokines which have been proposed to have a role in cachexia (57). However, future studies are still necessary to improve this potential use of AP-1 inhibitors in preclinical studies involving cancer cachexia.

Acknowledgements

This work was supported by grants from the Instituto de Salud Carlos III (03/0100) of the Ministerio de Sanidad y Consumo, from the Dirección General de Investigación Científica y Técnica (BFI2002-02186) of the Ministerio de Educación y Ciencia, and from the Generalitat of Catalunya (SGR/01018).

References


